Q1 Earnings Estimate for TRVI Issued By HC Wainwright

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst B. Folkes forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS and FY2030 earnings at $0.79 EPS.

A number of other equities analysts also recently issued reports on TRVI. Morgan Stanley cut their price objective on shares of Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. JonesTrading reduced their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Needham & Company LLC increased their price objective on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $21.60.

Trevi Therapeutics Trading Up 0.1%

NASDAQ TRVI opened at $10.70 on Thursday. The business has a fifty day simple moving average of $11.14 and a 200 day simple moving average of $10.93. Trevi Therapeutics has a 12 month low of $4.85 and a 12 month high of $14.39. The firm has a market capitalization of $1.37 billion, a P/E ratio of -33.44 and a beta of 0.94.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its position in Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock valued at $46,669,000 after purchasing an additional 3,993,325 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 6,434,655 shares of the company’s stock worth $80,562,000 after purchasing an additional 607,669 shares in the last quarter. Viking Global Investors LP increased its position in shares of Trevi Therapeutics by 232.4% during the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock valued at $46,929,000 after purchasing an additional 3,585,875 shares during the last quarter. Vivo Capital LLC increased its position in shares of Trevi Therapeutics by 13.5% during the 3rd quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock valued at $46,616,000 after purchasing an additional 606,765 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Trevi Therapeutics by 95.4% during the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after buying an additional 2,363,835 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics News Summary

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Company says it achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and regulatory de‑risking milestone that can drive long‑term value if trials and endpoints are favorable. Article Title
• Positive Sentiment: Q4 2025 results topped expectations — EPS of ($0.06) vs. consensus ~($0.0966). The beat and management commentary from the earnings call support near‑term credibility on execution. Earnings Transcript
• Positive Sentiment: Broker support remains strong: Needham raised its target to $24 (Buy) and HC Wainwright reiterated a Buy with a $21 target and updated EPS forecasts — analyst backing increases visibility for upside expectations. Broker Note HC Wainwright Details
• Positive Sentiment: D. Boral Capital reaffirmed a Buy and $19 target, adding to the cluster of buy ratings—positive for investor sentiment and analyst coverage breadth. Article Title
• Neutral Sentiment: Morgan Stanley lowered its price target from $19 to $18 but kept an Overweight rating — still positive sentimentually, but the cut trims some near‑term upside expectations. Article Title
• Negative Sentiment: JonesTrading trimmed its target from $25 to $24 (remains a Buy) — a modest downward adjustment in analyst upside that slightly cools the market’s price‑target momentum. Article Title

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.